There will be exams, tests and procedures to see if the patient is eligible for the study.
Some are part of regular cancer care and others are part of the study. Subjects will also
need to complete a research questionnaire at certain points in the study.
Subjects will receive treatment of avelumab and intravesical BCG until unacceptable toxicity
or tumor progression.
Study participation is up to three years.
1. Histologically or cytologically documented Non-muscle Invasive Bladder Cancer (NMIBC)
2. Patient with BCG-treated but unresponsive NMIBC (persistent or recurrent defined as
tumor lesion present after prior response).
3. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 to 2.
4. Patients who are able to understand and sign the informed consent form.
5. Age ≥ 18 years old
6. Ability to comply with protocol
7. Life expectancy >/=12 weeks
8. Adequate hematologic and end-organ function per protocol
1. Evidence of locally advanced or metastatic bladder cancer (including disease involving
renal pelvis, ureter, or prostatic urethra).
2. Evidence of muscle-invasive bladder cancer
3. Evidence of extravesical bladder cancer
4. Active central nervous system (CNS) metastases.
5. Prior treatment with PD-L1 inhibitor.
6. Prior radiation to bladder
7. Known additional malignancy that required active treatment within the last 2 years.
Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the
8. Patient is considered a poor medical risk that would interfere with cooperation with
the requirements of the study.
9. Patient has a condition or laboratory abnormality that might confound the study
results, or interfere with the patient's participation for the full duration of the
10. Patient has not recovered (i.e, to ≤Grade 1 or to baseline) from previous intravesical
BCG or other anti-cancer therapy induced AEs.
11. Treatment with any approved anti-cancer therapy, including chemotherapy (systemic or
intravesical), radiation therapy, or hormonal therapy within 3 weeks prior to the
first dose of study treatment
12. Treatment with any other investigational agent or participation in another clinical
study with therapeutic intent within 4 weeks prior to the first dose of study
13. Pregnant or lactating, or intending to become pregnant during the study
a. Women who are not postmenopausal (≥ 12 months of non−therapy-induced amenorrhea) or
surgically sterile must have a negative serum pregnancy test result within 14 days
prior to the first dose of study treatment.
14. History of severe allergic, anaphylactic, or other hypersensitivity reactions to
chimeric or humanized antibodies or fusion proteins
15. Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells
16. Allergy or hypersensitivity to components of the avelumab formulation
17. History of autoimmune disease defined per protocol
18. Prior allogeneic stem cell or solid organ transplantation
19. Current use of immunosuppressive medication defined per protocol
20. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis
obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active
pneumonitis on screening chest CT scan
a. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
21. Positive test for HIV
22. Active hepatitis B (positive hepatitis B surface antigen [HBsAg] test at screening);
a. Patients with past or resolved hepatitis B (HBV) infection (positive anti-hepatitis
B core antigen [anti-HBc] antibody test) are eligible. HBV DNA must be obtained in
these patients prior to the first dose of study treatment.
23. Active hepatitis C
a. Patients positive for hepatitis C virus (HCV) antibody are eligible only if
polymerase chain reaction assay is negative for HCV RNA.
24. Active infection requiring systemic therapy
25. Severe infections within 4 weeks prior to the first dose of study treatment, including
but not limited to hospitalization for complications of infection, bacteremia, or
26. Significant cardiovascular disease, such as cerebral vascular accident/stroke (< 6
months prior to enrollment), New York Heart Association cardiac disease (Class II or
greater), myocardial infarction within the previous 6 months, unstable arrhythmias, or
27. Administration of a live/attenuated vaccine within 4 weeks prior to the first dose of
study treatment, within 5 months following the administration of the last dose of
study drug, or anticipation that such a live/attenuated vaccine will be required
during the study
28. Other severe acute or chronic medical conditions defined per protocol